期刊文献+

HPLC测定奥美沙坦酯中的基因毒性杂质 被引量:2

Determination of Genotoxic Impurity in Olmesartan Medoxomil by HPLC
原文传递
导出
摘要 目的建立HPLC测定奥美沙坦酯中潜在的基因毒性杂质[杂质1:N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑,杂质2:N-三苯甲基-5-(4',4'-二溴甲基联苯-2-基)四氮唑]的含量和限度。方法采用Phenomenex C18柱(250 mm×4.6 mm,5μm);流动相:0.1%冰乙酸水溶液-0.1%冰乙酸乙腈溶液(15∶85);检测波长:254 nm;流速:1.5 m L·min-1;柱温:25℃。结果杂质1和杂质2均在0.030 97~0.247 7μg·m L^(-1)内线性良好(r分别为0.999 6和0.998 7),平均回收率分别为94.37%和94.43%,RSD分别为2.38%和2.72%(n=9)。结论该方法专属性强,准确、灵敏,可以作为奥美沙坦酯中基因毒性杂质1和杂质2的液相分析方法。 OBJECTIVE To establish a method of HPLC to determine the limit and content of potential genotoxic impurities: N-(triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl-) tetrazole(impurity 1), and N-(triphenylmethyl)-5-[4',4'-(dibromomethylbiphenyl)-2-yl]tetrazole(impurity 2) in active pharmaceutical substance Olmesartan Medoxomil qualitatively and quantitatively. METHODS The method was performed on Phenomenex C18 column(250 mm×4.6mm, 5 μm). And 0.1% glacial acetic acid in water(A) : 0.1% glacial acetic acid dissolved in acetonitrile(B) as the mobile phase which was 15∶85 with a flow rate at 1.5 m L·min^-1. The detection wavelength was 254 nm, and the temperature of column was 25 ℃. RESULTS The calibration curve for impurity 1 and impurity 2 was well linear in the range of 0.030 97-0.247 7 μg·m L^-1(r was 0.999 6 and 0.998 7, respectively). Average recovery for impurity 1 and impurity 2 was 94.37% and 94.43%, and RSD was 2.38% and 2.72%(n=9), separately. CONCLUSION The method is highly specific, accurate and sensitive, it can be used for the quality control of the genotoxic impurities 1 and impurities 2 of Olmesartan Medoxomil.
出处 《中国现代应用药学》 CAS CSCD 2017年第3期407-409,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 奥美沙坦酯 基因毒性杂质 高效液相色谱法 Olmesartan Medoxomil genotoxic impurity HPLC
  • 相关文献

参考文献3

二级参考文献32

  • 1吴泰志,刘晓华,张福利,谢美华.抗高血压药奥美沙坦酯合成新路线和相关杂质的研究[J].药学学报,2006,41(6):537-543. 被引量:14
  • 2何其林,耿玉先.一种奥美沙坦酯的制备方法:中国,1680335[P].2005-10-12.
  • 3ICH Q3A (R2), Impurities in New Drug Substances[ EB/OL]. (2006 - 10-25). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA422. pdf.
  • 4ICH Q3B (R2) Impurities in New Drug Substances [ EB/OL]. (2006 -06-02). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA421. pdf.
  • 5ICH Q3C ( R3 ) Impurities: Guideline for Residual Solvents [EB/OL]. (2005-11). [2014 -03 -31]. http://www, ieh. org/LOB/media/MEDIA423, pdf.
  • 6EMEA. Guideline on the limits of Genotoxic hnpurities [ EB/OL]. (2006 -06 - 28). [2014 -03 -31]. http://www. emea. europa, eu/pdfs/human/swp/519902en, pdf.
  • 7EMEA. Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities, Revision 1 [ S]. (2008 - 06 -26). [2014 -03 -31]. http://www, emea. europa, eu/pdfs/ human/swp/43199407en, pdf.
  • 8FDA. Guidance for Industry Genotoxic and Carcinogenic Impuri- ties in Drug Substances and Products: Recommended Approaches [S]. (2008-11). [2014 -03 -31]. http:// www. fda. gov/ downloads/drugs/guidance complianceregulat-ory information/guidances/ucm079235, pdf.
  • 9ICH. Assessment And Control Of DNA Reactive (Mutagenic) Im- purities In Pharmaceuticals To Limit Potential Carcinogenic Risk[S]. (2013 -02). [2014 -03 -31]. http://www, ieh. org/ product s/guidelines/multi-disciplinary / article/muhidisciplinary- guidelines, html.
  • 10ARIENS E.I. Domestication of chemistry by design of safer chemi- cals: structure-activity relationships[J]. Drug Metab Rev, 1984, 15 ( 3 ) :425 - 504.

共引文献93

同被引文献13

引证文献2

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部